G1 Therapeutics Receives $33,000,000 Series B Funding

  • Feed Type
  • Date
    2/5/2015
  • Company Name
    G1 Therapeutics
  • Mailing Address
    79 T.W. Alexander Drive Research Triangle Park, NC 27709 USA
  • Company Description
    G1 Therapeutics is working to commercialize a proprietary small molecule-based approach to protect the bone marrow from damage due to chemotherapy or radiation.
  • Website
    http://www.g1therapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $33,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    G1 plans to use the proceeds to advance its lead program G1T28, a highly potent and selective CDK4/6 inhibitor, through proof of concept as an antineoplastic agent and as a bone marrow chemoprotectant. G1T28 is currently being evaluated in Phase 1a clinical trials to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers. Data collected from this study will inform the dose and schedule for multiple Phase 1b / 2a clinical trials in cancer patients, which are expected to begin in 2015.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy